"Better" can't be answered from data, because the data don't exist. FDA's July 2026 review of BPC-157 states: "We found no human pharmacokinetic data for BPC-157 after oral, SC, nasal, or transdermal administration" [3]. Pharmacokinetic data are what would show how much of a dose reaches the blood, by each route. That briefing did not identify a published human measurement for those routes.
No published head-to-head result establishes a better route
The reviewed literature does not establish an oral-versus-injection benefit comparison. Oral and injected protocols are registered, including placebo-controlled studies, but their registrations do not provide the missing results. A 2026 systematic review found only three human studies of any kind, with 30 people in total, and none used capsules or under-the-skin shots [4].
The debate online runs on two things: animal studies, and reasoning about how peptides usually behave in the gut. Both are worth knowing. Neither tells you what happens when a person swallows a capsule or injects a vial.
| Route | Human absorption data | Human outcome data | Animal or lab data | FDA status |
|---|---|---|---|---|
| Oral capsule or tablet | None [3] | Registered tablet and gummy studies post no results [8] [1] | Reported stable in gastric juice in a lab dish (Veljaca 1995, as cited by FDA) [3] | Marketed as a supplement ingredient; not approved |
| Under-the-skin injection | None [3] | None [3] | Muscle injections in rats and dogs reached the blood [7] | Not FDA-approved; routine exemption not established |
| Injection into a knee or the bladder wall | Not measured | 16 knee-pain patients and 12 women, no control group [4] | Not applicable | Not FDA-approved; routine exemption not established |
| Intravenous infusion | Not measured | 2 adults, safety only, no control group [6] | Half-life 5.3 min in dogs, 15.2 min in rats [3] | Not FDA-approved; routine exemption not established |
| Nasal spray | None [3] | None | None identified | Not FDA-approved; routine exemption not established |
| Rectal enema | Not detected in blood in two studies [3] | One placebo-controlled abstract, 53 people; FDA judged it inadequate [3] | Not applicable | Not FDA-approved; routine exemption not established |
Forms as described in FDA's July 2026 briefing and the published studies. No form is FDA-approved.
The human enema measurements FDA reviewed
FDA described human plasma measurements after rectal enemas. In two enema studies from the early 2000s, researchers tested plasma for BPC-157 and did not detect it; one abstract said "most" levels were below what the assay could measure [3]. FDA's conclusion: "it does not appear that BPC-157 is absorbed systemically when given as a rectal enema" [3].
That result doesn't settle the oral question. The gut, the dose and the form all differ. It describes limited enema data, not a general proof about oral absorption or other formulations.
Does oral BPC-157 work? Registration is not a published result
Oral studies are registered, but the records reviewed here post no results. FDA's July 2026 briefing found no human pharmacokinetic data by mouth [3]. FDA also found no studies that gave BPC-157 to people with ulcerative colitis by mouth, the use it reviewed [3].
The main argument for capsules is a lab result. BPC-157 was reported to resist breakdown in gastric juice in vitro (Veljaca 1995, as cited by FDA) [3]. That was in a lab dish. Surviving stomach acid is one step; crossing the gut wall into the blood is another, and nobody has measured that in people.
A human study of oral tablets was registered. A phase 1 trial in healthy volunteers in Mexico planned to measure safety and blood levels, but the registry shows no results, and FDA could not find a published study from it [8] [3].
A newer oral-gummy registry reports 40 participants followed for eight weeks, with no control arm and no posted results [1]. It does not compare swallowing BPC-157 with an injection or provide the missing absorption measurements. Calling oral use entirely unstudied would miss this record; calling it effective would overstate it.
Can BPC-157 be taken orally? It's sold that way
Yes, it is sold in oral form. FDA notes that BPC-157 is marketed in the US as an ingredient in dietary-supplement capsules and tablets, and that the compounding nominations it reviewed proposed oral capsules among other forms [3]. Those are facts about the market. They say nothing about whether oral BPC-157 is absorbed or does anything in people.
FDA's review lists the forms BPC-157 is marketed in: oral capsule, oral spray, nasal spray and injectable [3]. No listed form is FDA-approved. The 503A bulks list does not establish a routine patient-care exemption for BPC-157 [2]. The full status is on whether BPC-157 is FDA-approved.
What about injections? Almost no human data either
The review included uncontrolled knee and bladder reports; registered under-the-skin protocols add research records, not published benefit results (FDA and registry sources) [4] [3]. The bladder study reported symptom relief in all 12 women and no adverse events, but it had no comparison group [5].
A two-person pilot gave BPC-157 by intravenous infusion and found no changes in heart, liver, kidney, thyroid or blood-sugar tests [6]. It measured safety markers over three days, not blood levels of the peptide or any benefit. Route does matter for one known risk: FDA notes that injected and nasal peptides are, in general, more likely to provoke an immune reaction than oral or rectal ones [3]. For the wider safety record, see whether BPC-157 is safe.
What animal data say about how long it lasts
In dogs and rats, intravenous BPC-157 had a half-life of 5.3 and 15.2 minutes, and blood levels rose with the dose after muscle injections (He 2022, as summarized by FDA) [7] [3]. Animal data; may not apply to people.
The same animal study measured how much of a muscle injection reached the blood: about 14% to 19% in rats and 45% to 51% in dogs [7]. The two species differ by roughly threefold, which is a reminder of how poorly animal numbers predict human ones. FDA added that without bioavailability data for the routes actually sold, even the animal injection safety results can't be used to set safe limits for those routes [3].
Approval and compounding status are separate from route
Whichever form you are looking at, the regulatory answer is the same. There is no FDA-approved BPC-157 product, and the current 503A bulks list does not establish a routine patient-care exemption [3]. Capsules marketed as supplements are not FDA-approved either. What that means for anyone trying to obtain it is covered in BPC-157's legal status for buyers.
Questions to ask a clinician
The route debate is a sign that the real question is about the condition. Bring that to a clinician instead.
- What is causing my injury, joint pain or gut symptoms, and which FDA-approved treatments fit?
- Is there a registered clinical trial I could qualify for?
- If I've already taken BPC-157, what should I tell you, and what would you watch for?
How we separate human, animal and lab evidence on pages like this is explained on how we check.